Eagle Pharmaceuticals (EGRX) announced yesterday that it renegotiated its revenue arrangement with Teva (TEVA), whereby the royalty rate on Bendeka sales would increase to 30% from 25% on October 1, 2019, and increase by 1% a year until the rate reaches 32%, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as a positive for Eagle shares. Based on his current Bendeka assumptions, he believes the announcement could be worth up to $5 per share. With Eagle Pharmaceuticals shares up 1.8% yesterday, the market appears to have overly discounted the potential upside from the news, says Folkes. He keeps an Overweight rating on the name with a $58 price target.